Eisai: FDA confirms enough data to move Alzheimer's drug to Phase III studies

TOKYO, Aug 9 (Reuters) - Japan's Eisai Co said on Tuesday the U.S. Food and Drug Administration had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer's disease.